Winston Must Face Claims Over $56M Merger: Judge

Law360, New York (July 12, 2011, 5:47 PM EDT) -- A New York state judge ruled Monday that Winston & Strawn LLP must face accusations from a biopharmaceutical company's shareholders that the firm botched drug licensing agreements so badly that it soured the company's $56 million sale to a hedge fund.

Although it was the pharmaceutical company, Biosynexus Inc., and not its shareholders, led by health care investment firm OrbiMed Advisors LLC, that had a retention agreement with Winston & Strawn, the circumstances of the case made an engagement letter unnecessary, Judge Judith J. Gische ruled....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.